



Goldrea updates Global Cannabinoid Lab Analytics progress

June 18, 2019 - Vancouver, British Columbia CSE:GOR, Frankfurt:GOJ, OTC-US:GORAF

Goldrea Resources Corp. (“Goldrea” or the “Company”) would like to update progress made on its cannabinoid product Testing Lab, operated by Goldrea’s wholly-owned subsidiary, Global Lab Analytics (“GLA”) located in Irvine, California. The Licensing Board of Irvine has completed the on-site inspection, moving toward full license to begin testing. The board also approved GLA to begin testing of non-cannabinoid items such as things as water and soil samples upon delivery of lab equipment. Final interview with senior staff and the city council is scheduled to be within twenty-one days. Lab testing equipment has been scheduled to be ordered and delivered upon certification.

Goldrea wishes to correct an error in its news release of March 27, 2019 and associated documentation. The amount of gross proceeds raised in the second tranche of its non-brokered private placement should be \$184,000.02 (through the issuance of 3,066,667 units) instead of \$175,000.

The Company is also postponing its shareholder meeting, which was previously set for July 12, 2019, in order to allow management more time to prepare documentation to present to shareholders and the Canadian Securities Exchange. The Company will announce the rescheduled date for the meeting once it is known.

For more information, please contact:
James Elbert, President and CEO
Telephone: (604) 559-7230
Email: jelbert@goldrea.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain “forward-looking statements”, which are statements about the future based on current expectations or beliefs. For this purpose, statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements by their nature involve risks and uncertainties, and there can be no assurance that such statements will prove to be accurate or true. Investors should not place undue reliance on forward-looking statements. The Company does not undertake any obligation to update forward-looking statements except as required by law.